



Article How Well Do Low Population-Specific Values for Muscle Parameters Associate with Indices of Poor Physical Health? Cross-Sectional Data from the Geelong Osteoporosis Study

Sophia X. Sui ^{1,*}, Kara L. Holloway-Kew ¹, Natalie K. Hyde ¹, Lana J. Williams ¹, Monica C. Tembo ¹, Emma West ¹ and Julie A. Pasco ^{1,2,3,4}

- ¹ IMPACT—Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC 3220, Australia; k.holloway@deakin.edu.au (K.L.H.-K.); natalie.hyde@deakin.edu.au (N.K.H.); l.williams@deakin.edu.au (L.J.W.); m.tembo@deakin.edu.au (M.C.T.); westem@deakin.edu.au (E.W.); julie.pasco@deakin.edu.au (J.A.P.)
- ² Department of Medicine–Western Campus, The University of Melbourne, St Albans, VIC 3010, Australia
- ³ Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3800, Australia
- ⁴ Barwon Health, University Hospital Geelong, Geelong, VIC 3220, Australia
- * Correspondence: sophia.sui@deakin.edu.au; Tel.: +61-3-4215-3306; Fax: +61-3-4215-3491



Keywords: sarcopenia; indices of poor physical health; cut-offs; muscle

1. Introduction

Sarcopenia is defined as reduced muscle mass and function with ageing [1,2]. Sarcopenia is considered a component of physical frailty in as much as it shares domains and measurements with frailty, in particular poor physical function and muscle strength [3–6].



Citation: Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Williams, L.J.; Tembo, M.C.; West, E.; Pasco, J.A. How Well Do Low Population- Specific Values for Muscle Parameters Associate with Indices of Poor Physical Health? Cross- Sectional Data from the Geelong Osteoporosis Study. J. Clin. Med. 2022, 11, 2906. https://doi.org/ 10.3390/jcm11102906

Academic Editor: Marco Alessandro Minetto

Received: 22 April 2022 Accepted: 15 May 2022 Published: 20 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Currently, there is no universally accepted operational definition for sarcopenia [3]. Further, there is confusion regarding inconsistencies in the thresholds applied to identify low muscle mass, muscle strength, and poor muscle function [3]. The most widely employed definitions are those from the European Working Group on Sarcopenia in Older People (EWGSOP) [1] and the Foundation for the National Institutes of Health (FNIH) in the USA [2]. We have reported that prevalence estimates for sarcopenia vary substantially in different geographic areas and also in homogeneous samples when different criteria and cut-off points are applied [7,8]. Nevertheless, despite these differences, sarcopenia and its components have consistently been associated with physical limitations [9], mental ill-health [10], and poor cognitive function [11,12].

Age-related or disease-induced health conditions, such as chronic disease, sensory and motor deficits, and physical and mental frailty, are associated with poor performance in walking, climbing, bending, and carrying [13]. These adverse health conditions are also associated with detrimental outcomes (including falls, fractures, and hospitalisations) that have significant impacts on social well-being [13–15] and quality of life [16–18]. Few studies have examined the association between the components of sarcopenia using population-specific values and indices of poor health [19]. Thus, we aimed to examine associations between measures of skeletal muscle deficits and indices of poor health, using cut-points that identify low values in the distribution of the same population.

2. Methods

2.1. Study Design

This cross-sectional analysis involved data from the 15-year follow-up phases of the Geelong Osteoporosis Study (GOS), collected from 2010 to 2014 for women and 2016 to 2019 for men. Detailed information about the GOS is published elsewhere [20]. Briefly, age-stratified samples of women and men were selected at random using the electoral roll as the sampling frame. In total, 1494 women were recruited from 1993–1997 (ages 20–93 years, 77% participation), and 1540 men were recruited from 2001–2006 (ages 20–96 years, 67% participation) and assessed at subsequent follow-up phases. The cohorts are essentially Caucasian (~98%).

2.2. Participants

A total of 894 women and 624 men participated in the 15-year follow-ups, respectively. Of these, 405 women and 347 men were aged \geq 60 years old and included in this analysis. Of the remaining participants, 358 women and 341 men provided HGS data, 323 women and 342 men provided ALM data, and 328 women and 340 men provided TUG data. Thus, data for identifying sarcopenia were available for 323 women and 342 men aged \geq 60 years (missing data: HGS men = 1; ALM women = 35; TUG women = 30, men = 2).

The study was approved by the Barwon Health Human Research Ethics Committee. Written informed consent was obtained from all participants.

2.3. Data

2.3.1. Anthropometry

Weight and height were measured to the nearest ± 0.1 kg and ± 0.01 m, and body mass index (BMI) was calculated as weight/height² (kg/m²).

2.3.2. Muscle strength

Handgrip strength (HGS, kg) was measured using an analogue hand-held dynamometer (Jamar, Sammons Preston, Bolingbrook, IL, USA) for women and an electronic hand-held dynamometer for men (Vernier, LoggerPro3). Trained researchers explained and demonstrated the testing procedure to each participant before measurement trials. With the participant seated in a comfortable position and the arm holding the dynamometer flexed at the elbow to 90 degrees, the participant was asked to squeeze the device as hard as possible for several seconds, and the peak reading was recorded. This procedure was repeated for each hand, and there was no time interval between trials. For men, the protocol was similar, except there was a 5-s interval between trials. Maximum values were used for analysis. HGS values measured with the Vernier device were transformed to Jamar equivalent values according to the following equation:

HGSJamar (kg) = $9.50 + 0.818 \times$ HGSVernier (kg) + $8.80 \times$ Sex

where sex = 1 for men, that was developed by measuring maximum HGS on each device for 45 men and women aged 21–67 years, as previously described [8].

2.3.3. Timed up and Go Test

Timed Up and Go (TUG), a test of mobility that involves static and dynamic balance [21], involved measuring the time taken (in seconds) by the participant to stand up from a chair (without armrests), walk to a marked line (3 m distance), turn around then return to the chair and sit down.

2.3.4. Lean Mass

Lean mass, a proxy measure for muscle mass, was obtained from whole-body dualenergy X-ray absorptiometry (DXA; Lunar Prodigy-Pro, Madison, WI, USA); appendicular lean mass (ALM) was equivalent to the sum of lean mass for the arms and legs. ALM was expressed relative to height as ALM/height² (kg/m²) and BMI as ALM/BMI (m²).

2.4. Population-Specific Values for Sarcopenia Components

Population-specific cut-points were determined as equivalent to two standard deviations (SDs) below sex-specific mean values for young reference groups (ages \leq 49 years) generated from the same population [22–25]. For women, the cut-point for low HGS was <16 kg [24] and, for men, <31 kg [8]. Low lean mass was identified as ALM/height² <5.3 kg/m² for women and <6.94 kg/m² for men [22], low ALM/BMI as <0.512 m² for women and <0.827 m² for men [23]. Using the same approach, we calculated that the cut-off for low TUG was >9.3 s for women and >9.9 s for men.

2.5. Indices of Poor Health

Fractures (excluding fractures of the skull, face, fingers, and toes as well as those occurring from high trauma) were ascertained by self-report and confirmed using radio-logical reports. Fractures were included in the analyses if there was at least one incident fracture since the age of 50 years. There were more fractures than participants with fractures because some participants had sustained more than one fracture. Falls in the past 12 months and hospitalisations in the past month were self-reported. For fractures, falls, and hospitalisations, at least one (in each case) was considered an index of poor health. We used the Research Electronic Data Capture tool (hosted by Barwon Health) to collect and manage these data [26].

2.6. Statistical Analysis

Analyses were conducted using IBM SPSS (V24, USA) and Minitab (v18, USA). The data were visually checked for normality using histograms. Logistic regression models were developed to investigate the association between sarcopenia parameters and the indices of poor health. The dependent variable (falls, fractures, and hospitalisations) corresponds to odd ratios of the independent variable (sarcopenia parameters using GOS population-specific, EWGSOP2, and FNIH cut-offs). Potential covariates tested in the models included age and sex. Interaction terms were checked in the final models.

Furthermore, we estimated cut-points for HGS, TUG, ALM/height², and ALM/BMI that best discriminated the presence or absence of indices of poor health. Similar to our previous study, the location of each optimal cut-point was determined by the principle that the sensitivity and specificity are closest to the value of the area under the Receiver

Operating Characteristic (ROC) curve, and the absolute value of the difference between the sensitivity and specificity is the smallest [27].

3. Results

3.1. Participant Characteristics

Table 1 shows the participant characteristics. Participants' ages ranged from 60 to 96 years, and the mean BMI was in the overweight category. There were 177 (25.3%) participants with at least one fall and 38 (5.4%) with two or more falls over the past 12 months. There were 94 who had fractures since the age of 50 years (rib 14, wrist 13, ankle 9, humerus 8, spine 7, foot 7, forearm 6, patella 6, shoulder 6, tibia 6, hand 5, hip 4, clavicle 3, femur 3, fibula 3). There were 48 (6.9%) participants who had been hospitalised during the previous month.

Table 1. Participant characteristics. Data are expressed as mean (\pm SD) or median (IQR) or *n* (%).

	Total	Women	Men				
	<i>N</i> = 665	<i>N</i> = 323	<i>N</i> = 342				
Age (year)	71 (65–78)	70 (64–75)	70.0 (66–78)				
Anthropometry							
Weight (kg)	78.9 (±15.7)	73.9 (±15.4)	83.9 (±13.8)				
Height (m)	1.66 (±0.09)	1.59 (±0.06)	1.73 (±0.07)				
BMI (kg/m^2)	28.6 (±5.2)	29.1 (±6.0)	28.1 (±4.1)				
Sarcopenia components							
HGS (kg)	29 (±1.0)	23 (±6)	37 (±6)				
ALM/height ² (kg/m ²)	7.44 (±1.20)	6.59 (±0.79)	8.25 (±0.93)				
ALM/BMI (m ²)	0.74 (±0.19)	0.59 (±0.10)	0.89 (±0.12)				
TUG (s)	9.2 (8.0–10.9)	9.1 (7.9–10.8)	9.2 (8.0–10.7)				
Indices of poor health							
Hospitalisation (≥ 1 in past month)	48 (6.9%)	23 (6.5%)	25 (7.4%)				
Fracture (≥ 1 since age 50 year)	94 (13.4%)	58 (16.2%)	36 (10.5%)				
Falls (≥ 1 in the past 12 month)	177 (25.3%)	110 (30.7%)	67 (19.6%)				

HGS: handgrip strength; ALM: appendicular lean mass; ALM/BMI: appendicular lean mass/body mass index; TUG: Timed Up and Go (TUG) test.

3.2. Associations between Low Muscle Parameters and Indices of Poor Health

Table 2 shows odds ratios (OR) and 95% confidence intervals (95% CIs) for the associations between low muscle parameters and indices of poor health before and after adjusting for age and sex. For all cut-points, low HGS was consistently associated with falls (\geq 1). Low HGS was associated with hospitalisation when using EWGSOP2 criteria. There was little evidence to support an association between ALM, using any cut-point, and indices of poor health. No interaction terms were detected in any models.

3.3. Cut-Offs of Skeletal Muscle Deficits Obtained Using Receiver Operating Characteristic Curves

The cut-off for HGS that best predicted falls (\geq 1) was 17.5 kg for women (sensitivity 0.86, specificity 0.35; area under the curve: 0.62 95% CI 0.55–0.69; *p* < 0.001); and 33.5 kg for men (sensitivity 0.72, specificity 0.44; area under the curve: 0.60 95% CI 0.52–0.67; *p* = 0.02). The TUG test cut-off was 8.6 s for women (sensitivity 0.73, specificity 0.38; area under the curve: 0.61 95% CI 0.54–0.68; *p* = 0.001); and 9.9 s for men (sensitivity 0.59, specificity 0.70; area under the curve: 0.69 95% CI 0.62–0.77; *p* < 0.001). ALM/height² was 6.20 kg/m² for women (sensitivity 0.74, specificity 0.43; area under the ROC curve: 0.55 95% CI 0.48–0.62; *p* = 0.18); and 7.46 kg/m² for men (sensitivity 0.86, specificity 0.27; area under the curve: 0.55 95% CI 0.47–0.63; *p* = 0.25); ALM/BMI was <0.61 m² for women (sensitivity 0.43, specificity 0.72; area under the curve: 0.56 95% CI 0.50–0.63; *p* = 0.07); 0.91 m² for men (sensitivity 0.46, specificity 0.72; area under the curve: 0.60 95% CI 0.53–0.68; *p* = 0.009).

		Unadjusted		Adjusted for Age and Sex	
Sarcopenia Indicators (Predictors)	Indices of Poor Health (Outcomes)	Odds Ratios (95% CI)	p Value	Odds Ratios (95% CI)	p Value
ALM/BMI _{GOS}					
	Hospitalisation (≥ 1 in past month)	1.23 (0.64–2.36)	0.54	1.10 (0.56–2.16)	0.79
	Fracture (≥ 1 since age 50 year)	1.17 (0.72–1.93)	0.53	1.17 (0.70–1.95)	0.54
	Falls (≥ 1 in the past 12 month)	1.51 (1.03–2.22)	0.03	1.43 (0.96–2.14)	0.08
ALM/height ² GOS					
	Hospitalisation (≥ 1 in past month)	0.82 (0.19–3.54)	0.79	0.68 (0.16–3.02)	0.62
	Fracture (≥ 1 since age 50 year)	1.64 (0.49–5.48)	0.42	1.73 (0.51–5.87)	0.38
	Falls (≥ 1 in the past 12 month)	1.43 (0.68–2.98)	0.35	1.22 (0.57–2.63)	0.61
HGS _{GOS}					
	Hospitalisation (≥ 1 in past month)	1.86 (0.99–3.49)	0.05	1.54 (0.76–3.10)	0.23
	Fracture (\geq 1 since age 50 year)	1.36 (0.82–2.25)	0.24	1.17 (0.67–2.04)	0.59
	Falls (≥ 1 in the past 12 month)	2.44 (1.66–3.58)	<0.001	2.04 (1.33–3.14)	0.001
TUG _{GOS}					
	Hospitalisation (≥ 1 in past month)	0.73 (0.39–1.34)	0.30	0.89 (0.44–1.80)	0.74
	Fracture (\geq 1 since age 50 year)	0.56 (0.35–0.88)	0.01	0.63 (0.38–1.05)	0.08
	Falls (in the past 12 months)	0.14 (0.29–0.59)	<0.001	0.58 (0.38–0.87)	0.008
ALM/height ² EWGSOP2					
	Hospitalisation (≥ 1 in past month)	1.18 (0.41–3.45)	0.76	1.02 (0.34–3.04)	0.97
	Fractures (≥ 1 since age 50 year)	1.26 (0.57–2.78)	0.57	1.15 (0.51–2.58)	0.73
	Falls (≥ 1 in the past 12 month)	1.44 (0.77–2.67)	0.25	1.14 (0.60–2.18)	0.69
HGS _{EWGSOP2}					
	Hospitalisation (≥ 1 in past month)	3.28 (1.54–7.00)	0.002	3.23 (1.35–7.78)	0.009
	Fracture (≥ 1 since age 50 year)	1.95 (1.01–3.77)	0.05	1.38 (0.67–2.84)	0.39
	Falls (in the past 12 month)	3.24 (1.88–5.57)	<0.001	1.87 (1.03–3.38)	0.04
TUG _{EWGSOP2}					
	Hospitalisation (≥ 1 in past month)	0.59 (0.13–2.64)	0.59	0.80 (0.17–3.74)	0.77
	Fracture (\geq 1 since age 50 year)	055 (0.18–1.70)	0.30	0.67 (0.21–2.16)	0.50
	Falls (≥ 1 in the past 12 month)	0.14 (0.05–0.37)	<0.001	0.20 (0.07–0.56)	0.002
ALM/BMI _{FNIH}					
	Hospitalisation (≥ 1 in past month)	1.36 (0.68–2.71)	0.38	1.25 (0.62–2.53)	0.53
	Fractures (\geq 1 since age 50 year)	1.20 (0.71–2.04)	0.50	1.12 (0.65–1.92)	0.68
	Falls (≥ 1 in the past 12 month)	1.38 (0.91–2.08)	0.13	1.17 (0.77–1.80)	0.46
HGS _{FNIH}					
	Hospitalisation (≥ 1 in past month)	2.55 (1.13–5.77)	0.02	2.37 (0.93-6.01)	0.07
	Fractures (≥ 1 since age 50 year)	2.10 (1.08–4.07)	0.03	1.47 (0.71–3.05)	0.28
	Falls (≥ 1 in the past 12 month)	3.34 (1.92–5.82)	<0.001	1.90 (1.03–3.48)	0.04

Table 2. Odds ratios (OR 95% confidence interval) of binary logistic models for the associations between low muscle parameters and indices of poor health.

GOS: Geelong Osteoporosis Study; HGS: handgrip strength; ALM: appendicular lean mass; ALM/BMI: appendicular lean mass/body mass index; TUG: Timed Up and Go (TUG); EWGSOP2: the European Working Group on Sarcopenia in Older People (revised); FNIH: the Foundation for the National Institutes of Health.

4. Discussion

In this study, we report associations between measures of skeletal muscle deficits and indices of poor health, using different cut-points to identify low values. Overall, muscle strength performed better than lean mass measures for indicating poor indices of health. In particular, HGS and TUG were consistently associated with falls, regardless of the cut-offs applied. Lean mass measures were not associated with falls, fractures, or hospitalisations. Further, we determined optimal point estimates for skeletal muscle deficits that identify indices of poor health, including falls, fractures, and hospitalisation.

The current study found that HGS, regardless of cut-off, is a predictor of falls. Using data from 353 men and 245 women aged 65–98 years from the same study, we have previously reported that sarcopenic obesity was associated with an increased risk of falls and emphasised that physical performance substantially contributed to the identified associations [28]. Similarly, a recent study from Turkey also reported that individuals with sarcopenic obesity had a higher risk for falls compared to those without sarcopenic obesity [29]. The cross-sectional study involved 423 men and women aged \geq 65 years, and sarcopenia was categorised according to EWGSOP1 using population-specific (Turkish) cut-off points. Body composition parameters were assessed using a bioelectrical impedance analyser. A recent cross-sectional Australian study by Kirk et al. examined the association between sarcopenia and health indicators in older individuals [19]. This study included 356 people (median age 79 years, 24.8% men) from the community. Sarcopenia was defined using low HGS and gait speed cut-offs recommended by Sarcopenia Definitions and Outcomes Consortium. The health outcomes included falls, fractures (past 5 years), malnutrition, depression, balance confidence, fear of falling, static balance, dynamic balance, and body composition. The study reported that sarcopenia was positively associated with malnutrition, depression, fear of falling as well as recurrent falls and fractures and negatively associated with poor balance confidence. In our current study, sarcopenia parameters were not observed to be associated with fractures. The point estimates for fractures seem to suggest a pattern of poor muscle and higher fracture risk; however, there could be less statistical power to detect the significant relationships. A systematic review and meta-analysis [30] reported similar results that sarcopenia was associated with a higher rate of falls and a higher incidence of hospitalisations; however, it was unclear whether sarcopenia was associated with the incidence of fractures. This review focused on longitudinal studies (range of follow-up: 3 months to 9.8 years), and only studies that used the EWGSOP1 criteria to diagnose sarcopenia were included.

Another systematic review and meta-analysis, including nine prospective studies, examined associations between sarcopenia and the risk of fractures among communitydwelling older adults [31]. The sarcopenia definitions considered were the EWGSOP, FNIH, International Working Group for Sarcopenia (IWGS), and Asian Working Group for Sarcopenia (AWGS). An association between sarcopenia and fractures was observed only for men when applying the AWGS definition [31]. Another systematic review and meta-analysis included five cohort studies with a total of 27,990 participants [32], showing that sarcopenia was associated with incident fracture.

In the current study, only HGS using EWGSOP2 was associated with hospitalisation. In contrast, a systematic literature review reported that sarcopenia predicted hospitalisation in older women regardless of the specific population or the sarcopenia definition used [33]. This review included a total of 2832 participants in five studies and demonstrated that sarcopenia was associated with hospitalisation in community and hospital settings in both cross-sectional and longitudinal studies. It is possible that our study was underpowered to detect such an association.

A systematic literature review assessed associations between sarcopenia with falls and fractures among older adults [34]. Thirty-six studies (52,838 individuals) were included in the systematic review, while thirty-three studies (45,926 individuals) were included in the meta-analysis. This article revealed that people with sarcopenia had a higher risk of falls

and fractures compared with those without sarcopenia, which was independent of study design, population, sex, sarcopenia definition, continent, and study quality.

The TUG test was included as a component of sarcopenia in EWGSOP2. In our study, we consistently found that a poor TUG test time was associated with falls. This confirms the TUG test as a predictor for falls. Since the TUG test was devised in 1991, reports of optimal cut-offs for increased fall risk have ranged from 10 to 33 s [35–37]. A recent study (2021) [38] that evaluated the reliability and validity of the TUG test to predict falls in the elderly included 148 participants aged 60–90+ years, of whom 58 reported a fall in the previous year. Similar to our study, optimal TUG cut-points for predicting falls were determined using ROC curves. As the calculated cut-points increased for increasing age groups, the authors suggested that age-specific cut-points should be used.

Given the nature of the dataset utilised, this study was able to apply both populationspecific cut-offs and criteria recommended by the EWGSOP and FNIH. The current crosssectional study minimised the variance that arises naturally from differing participant characteristics in multiple samples. Falls and hospitalisations were self-reported, which may have been affected by recall bias. However, although we relied on some self-reported data, fractures were confirmed using radiological reports.

In conclusion, muscle strength and performance performed better than lean mass measures for indicating poor indices of health. These findings add to the growing evidence base to inform decisions regarding the selection of skeletal muscle parameters and their optimal cut-points for identifying sarcopenia.

Author Contributions: All authors had taken responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: S.X.S. and J.A.P. Drafting of the manuscript: S.X.S. Acquisition, analysis, or interpretation of data: S.X.S., K.L.H.-K., N.K.H., L.J.W., M.C.T., E.W. and J.A.P. Critical revision of the manuscript for intellectual content: all authors. Statistical analysis: S.X.S. All authors have read and agreed to the published version of the manuscript.

Funding: The Geelong Osteoporosis Study was funded by the National Health and Medical Research Council (NHMRC) Australia (projects 251638, 628582). S.X.S. was supported by an Executive Dean Health Research Fellowship. K.L.H.-K. was supported by an Alfred Deakin Postdoctoral Research Fellowship, N.K.H. by a Dean's Research Postdoctoral Fellowship (Deakin University) and L.J.W. by a NHMRC Emerging Leadership Fellowship (1174060). J.A.P. has received speaker fees from Amgen, Eli Lilly and Sanofi-Aventis and funding from the NHMRC, MRFF, Barwon Health, Deakin University, Amgen, the BUPA Foundation, Osteoporosis Australia, the Australian and New Zealand Bone and Mineral Society, the Geelong Community Foundation, Western Alliance, and the Norman Beischer Foundation. The funding organisations played no role in the design or conduct of the study, in the collection, management, analysis and interpretation of the data, nor in the preparation, review and approval of the manuscript.

Institutional Review Board Statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Human Research Ethics Committee at Barwon Health.

Informed Consent Statement: Written, informed consent was obtained from all participants in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors acknowledge the participants who participated in the study, and the staff who contributed to the data collection.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyere, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* 2019, *48*, 16–31. [CrossRef] [PubMed]
- Studenski, S.A.; Peters, K.W.; Alley, D.E.; Cawthon, P.M.; McLean, R.R.; Harris, T.B.; Ferrucci, L.; Guralnik, J.M.; Fragala, M.S.; Kenny, A.M.; et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, 547–558. [CrossRef] [PubMed]
- 3. Sui, S.X.; Williams, L.J.; Holloway-Kew, K.L.; Hyde, N.K.; Pasco, J.A. Skeletal muscle health and cognitive function: A narrative review. *Int. J. Mol. Sci.* 2020, 22, 255. [CrossRef] [PubMed]
- Tembo, M.C.; Holloway-Kew, K.L.; Mohebbi, M.; Sui, S.X.; Hosking, S.M.; Brennan-Olsen, S.L.; Williams, L.J.; Kotowicz, M.A.; Pasco, J.A. The association between a fracture risk tool and frailty: Geelong Osteoporosis Study. *BMC Geriatr.* 2020, 20, 196. [CrossRef]
- Tembo, M.C.; Mohebbi, M.; Holloway-Kew, K.L.; Gaston, J.; Brennan-Olsen, S.L.; Williams, L.J.; Kotowicz, M.A.; Pasco, J.A. The Predictability of Frailty Associated with Musculoskeletal Deficits: A Longitudinal Study. *Calcif. Tissue Int.* 2021, 109, 525–533. [CrossRef]
- Tembo, M.C.; Mohebbi, M.; Holloway-Kew, K.L.; Gaston, J.; Sui, S.X.; Brennan-Olsen, S.L.; Williams, L.J.; Kotowicz, M.A.; Pasco, J.A. The contribution of musculoskeletal factors to physical frailty: A cross-sectional study. *BMC Musculoskelet. Disord.* 2021, 22, 921. [CrossRef]
- Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Williams, L.J.; Tembo, M.C.; Leach, S.; Pasco, J.A. Prevalence of sarcopenia employing population-specific cut-points: Cross-sectional data from the Geelong Osteoporosis Study, Australia. J. Clin. Med. 2021, 10, 343. [CrossRef]
- Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Williams, L.J.; Tembo, M.C.; Leach, S.; Pasco, J.A. Definition-specific prevalence estimates for sarcopenia in an Australian population: The Geelong Osteoporosis Study. JCSM Cli. Rep. 2020, 5, 89–98. [CrossRef]
- 9. Santilli, V.; Bernetti, A.; Mangone, M.; Paoloni, M. Clinical definition of sarcopenia. *Clin. Cases Miner Bone Metab.* 2014, 11, 177–180. [CrossRef]
- Pasco, J.A.; Sui, S.X.; West, E.C.; Holloway-Kew, K.L.; Hyde, N.K.; Stuart, A.L.; Gaston, J.; Williams, L.J. Operational definitions of sarcopenia should consider depressive symptoms. *JCSM Clin. Rep.* 2021, *6*, 62–68. [CrossRef]
- 11. Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Williams, L.J.; Leach, S.; Pasco, J.A. Muscle strength and gait speed rather than lean mass are better indicators for poor cognitive function in older men. *Sci. Rep.* **2020**, *10*, 10367. [CrossRef] [PubMed]
- Pasco, J.A.; Stuart, A.L.; Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Tembo, M.C.; Rufus-Membere, P.; Kotowicz, M.A.; Williams, L.J. Dynapenia and low Cognition: A cross-sectional association in postmenopausal women. *J. Clin. Med.* 2021, 10, 173. [CrossRef] [PubMed]
- 13. Leirós-Rodríguez, R.; Romo-Pérez, V.; García-Soidán, J.L.; Soto-Rodríguez, A. Prevalence and Factors Associated with Functional Limitations during Aging in a Representative Sample of Spanish Population. *Phys. Occup. Ther.* **2018**, *36*, 156–167. [CrossRef]
- 14. Dionyssiotis, Y. Analyzing the problem of falls among older people. Int. J. Gen. Med. 2012, 5, 805–813. [CrossRef]
- 15. Antela, B.; Leirós-Rodríguez, R.; Soidán, J.L. Compliance with the recommendations of the World Health Organization on the practice of physical activity in people over 65 years in Spain. *J. Hum. Sport* **2020**, *17*, 29–38. [CrossRef]
- 16. Abimanyi-Ochom, J.; Watts, J.J.; Borgström, F.; Nicholson, G.C.; Shore-Lorenti, C.; Stuart, A.L.; Zhang, Y.; Iuliano, S.; Seeman, E.; Prince, R.; et al. Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS). *Osteoporos Int.* **2015**, *26*, 1781–1790. [CrossRef]
- Briggs, A.M.; Sun, W.; Miller, L.J.; Geelhoed, E.; Huska, A.; Inderjeeth, C.A. Hospitalisations, admission costs and re-fracture risk related to osteoporosis in Western Australia are substantial: A 10-year review. *Aust. N. Z. J. Public Health* 2015, 39, 557–562. [CrossRef]
- 18. Monagle, S. Reducing falls in community dwelling elderly. The role of GP care planning. Aust. Fam. Physician 2002, 31, 1111–1115.
- 19. Kirk, B.; Zanker, J.; Bani Hassan, E.; Bird, S.; Brennan-Olsen, S.; Duque, G. Sarcopenia Definitions and Outcomes Consortium (SDOC) Criteria are Strongly Associated With Malnutrition, Depression, Falls, and Fractures in High-Risk Older Persons. *J. Am. Med. Dir. Assoc.* **2021**, *22*, 741–745. [CrossRef]
- Pasco, J.A.; Nicholson, G.C.; Kotowicz, M.A. Cohort profile: Geelong Osteoporosis Study. Int. J. Epidemiol. 2012, 41, 1565–1575. [CrossRef]
- 21. Podsiadlo, D.; Richardson, S. The Timed "Up & Go": A test of basic functional mobility for frail elderly persons. *J. Am. Geriatr. Soc.* **1991**, *39*, 142–148. [CrossRef] [PubMed]
- Gould, H.; Brennan, S.L.; Kotowicz, M.A.; Nicholson, G.C.; Pasco, J.A. Total and appendicular lean mass reference ranges for Australian men and women: The Geelong osteoporosis study. *Calcif. Tissue Int.* 2014, 94, 363–372. [CrossRef] [PubMed]
- Pasco, J.A.; Holloway-Kew, K.L.; Tembo, M.C.; Sui, S.X.; Anderson, K.B.; Rufus-Membere, P.; Hyde, N.K.; Williams, L.J.; Kotowicz, M.A. Normative data for lean mass using FNIH criteria in an Australian setting. *Calcif. Tissue Int.* 2019, 104, 475–479. [CrossRef] [PubMed]
- Sui, S.X.; Holloway-Kew, K.L.; Hyde, N.K.; Williams, L.J.; Tembo, M.C.; Mohebbi, M.; Gojanovic, M.; Leach, S.; Pasco, J.A. Handgrip strength and muscle quality in Australian women: Cross-sectional data from the Geelong Osteoporosis Study. J. Cachexia Sarcopenia Muscle 2020, 11, 690–697. [CrossRef] [PubMed]

- Pasco, J.A.; Stuart, A.L.; Holloway-Kew, K.L.; Tembo, M.C.; Sui, S.X.; Anderson, K.B.; Hyde, N.K.; Williams, L.J.; Kotowicz, M.A. Lower-limb muscle strength: Normative data from an observational population-based study. *BMC Musculoskelet. Disord.* 2020, 21, 89. [CrossRef] [PubMed]
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadatadriven methodology and workflow process for providing translational research informatics support. *J. Biomed. Inform.* 2009, 42, 377–381. [CrossRef]
- 27. Unal, I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. *Comput. Math Methods Med.* 2017, 2017, 3762651. [CrossRef]
- Pasco, J.A.; Sui, S.X.; Tembo, M.C.; Holloway-Kew, K.L.; Rufus, P.G.; Kotowicz, M.A. Sarcopenic obesity and falls in the elderly. J. Gerontol. Geriatri. Res. 2018, 7, 465. [CrossRef]
- Öztürk, Z.A.; Türkbeyler, İ.H.; Abiyev, A.; Kul, S.; Edizer, B.; Yakaryılmaz, F.D.; Soylu, G. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. *Intern Med. J.* 2018, 48, 973–981. [CrossRef]
- 30. Beaudart, C.; Zaaria, M.; Pasleau, F.; Reginster, J.Y.; Bruyère, O. Health outcomes of sarcopenia: A systematic review and meta-analysis. *PLoS ONE* 2017, *12*, e0169548. [CrossRef]
- Zhang, Y.; Hao, Q.; Ge, M.; Dong, B. Association of sarcopenia and fractures in community-dwelling older adults: A systematic review and meta-analysis of cohort studies. *Osteoporos Int.* 2018, 29, 1253–1262. [CrossRef] [PubMed]
- 32. Chen, H.; Ma, J.; Liu, A.; Cui, Y.; Ma, X. The association between sarcopenia and fracture in middle-aged and elderly people: A systematic review and meta-analysis of cohort studies. *Injury* **2020**, *51*, 804–811. [CrossRef] [PubMed]
- 33. Zhang, X.; Zhang, W.; Wang, C.; Tao, W.; Dou, Q.; Yang, Y. Sarcopenia as a predictor of hospitalization among older people: A systematic review and meta-analysis. *BMC Geriatr.* **2018**, *18*, 188. [CrossRef] [PubMed]
- Yeung, S.S.Y.; Reijnierse, E.M.; Pham, V.K.; Trappenburg, M.C.; Lim, W.K.; Meskers, C.G.M.; Maier, A.B. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* 2019, 10, 485–500. [CrossRef]
- 35. Thomas, J.I.; Lane, J.V. A pilot study to explore the predictive validity of 4 measures of falls risk in frail elderly patients. *Arch. Phys. Med. Rehabil.* **2005**, *86*, 1636–1640. [CrossRef]
- 36. Arnold, C.M.; Faulkner, R.A. The history of falls and the association of the timed up and go test to falls and near-falls in older adults with hip osteoarthritis. *BMC Geriatr.* 2007, 7, 17. [CrossRef]
- Rose, D.J.; Jones, C.J.; Lucchese, N. Predicting the Probability of Falls in Community-Residing Older Adults Using the 8-Foot Up-and-Go: A New Measure of Functional Mobility. *J. Aging Phys. Act.* 2002, 10, 466–475. [CrossRef]
- Ugarte Ll, J.; Vargas, R.F. Timed up and go values in older people with and without a history of falls. *Rev. Med. Chil.* 2021, 149, 1302–1310. [CrossRef]